Table 2.
Univariate analysis of primary cohort (N = 180).
| OS | PFS | ||||||
|---|---|---|---|---|---|---|---|
| p | HR | 95% CI | p | HR | 95% CI | ||
| Sex | (Male vs Female) | 0.599 | 1.113 | 0.746-1.663 | 0.117 | 1.371 | 0.924-2.033 |
| Age | 0.001 | 1.030 | 1.013-1.048 | 0.403 | 1.007 | 0.991-1.022 | |
| NLR | 0.021 | 1.025 | 1.004-1.047 | 0.036 | 1.029 | 1.002-1.057 | |
| PLR | 0.014 | 1.001 | 1.000-1.002 | 0.170 | 1.001 | 1.000-1.002 | |
| LMR | 0.965 | 1.000 | 0.979-1.023 | 0.610 | 0.994 | 0.971-1.018 | |
| D-D | 0.153 | 1.000 | 1.000-1.000 | 0.019 | 1.000 | 1.000-1.000 | |
| FIB | 0.265 | 1.053 | 0.962-1.152 | 0.019 | 1.098 | 1.016-1.187 | |
| ALB | 0.021 | 0.962 | 0.931-0.994 | 0.102 | 0.975 | 0.945-1.005 | |
| Cholesterol | 0.346 | 0.933 | 0.807-1.078 | 0.560 | 0.963 | 0.847-1.094 | |
| Triglyceride | 0.420 | 1.089 | 0.885-1.341 | 0.994 | 1.001 | 0.821-1.220 | |
| HDL | <0.001 | 0.328 | 0.181-0.594 | 0.019 | 0.542 | 0.324-0.906 | |
| GGT | <0.001 | 1.006 | 1.003-1.009 | 0.044 | 1.003 | 1.000-1.006 | |
| UA | <0.001 | 1.003 | 1.002-1.005 | <0.001 | 1.004 | 1.002-1.006 | |
| CEA | 0.004 | 1.001 | 1.000-1.002 | 0.122 | 1.001 | 1.000-1.002 | |
| CA199 | 0.002 | 1.001 | 1.000-1.001 | <0.001 | 1.001 | 1.000-1.001 | |
| BMI | 0.472 | 0.981 | 0.932-1.033 | 0.733 | 1.008 | 0.961-1.057 | |
| Histologic differentiation (poor vs moderate/well) | 0.442 | 1.223 | 0.732-2.042 | 0.488 | 1.187 | 0.732-1.925 | |
| Tumor location | L | ||||||
| M | 0.099 | 0.597 | 0.324-1.103 | 0.28 | 0.749 | 0.443-1.266 | |
| U | 0.552 | 0.843 | 0.481-1.479 | 0.872 | 0.958 | 0.567-1.618 | |
| Her2 | (Yes vs no) | 0.942 | 0.958 | 0.303-3.024 | 0.346 | 1.485 | 0.653-3.38 |
| Family history | (Yes vs no) | 0.272 | 0.524 | 0.165-1.662 | 0.514 | 0.742 | 0.303-1.818 |
| Surgery | (Yes vs no) | 0.009 | 0.6 | 0.41-0.878 | 0.041 | 0.696 | 0.492-0.985 |
| Chemotherapy | (Yes vs no) | <0.001 | 0.355 | 0.242-0.521 | 0.04 | 0.643 | 0.422-0.98 |
| Radiotherapy | (Yes vs no) | 0.196 | 0.663 | 0.356-1.236 | 0.107 | 0.624 | 0.352-1.107 |
| Target therapy | (Yes vs no) | 0.023 | 0.434 | 0.212-0.892 | 0.49 | 0.828 | 0.484-1.416 |
| Peritoneal metastasis | (Yes vs no) | 0.291 | 1.251 | 0.825-1.896 | 0.496 | 1.141 | 0.78-1.669 |
| Liver metastasis | (Yes vs no) | 0.839 | 0.961 | 0.652-1.415 | 0.297 | 0.82 | 0.565-1.19 |
| Bone metastasis | (Yes vs no) | 0.751 | 0.875 | 0.385-1.991 | 0.703 | 0.862 | 0.403-1.845 |
| Lung metastasis | (Yes vs no) | 0.017 | 2.076 | 1.137-3.789 | 0.436 | 1.292 | 0.678-2.465 |
| Ovary metastasis (yes vs no) | 0.75 | 1.133 | 0.524-2.451 | 0.65 | 0.827 | 0.364-1.879 | |
| Distant lymph node metastasis | (Yes vs no) | 0.031 | 1.475 | 1.037-2.1 | 0.366 | 1.162 | 0.839-1.608 |
| Histologic type (others v adenocarcinoma) | 0.372 | 1.240 | 0.773-1.990 | 0.240 | 1.311 | 0.835-2.060 | |
| T stage | (T4 vs T3) | 0.711 | 0.919 | 0.590-1.434 | 0.011 | 0.616 | 0.424-0.895 |
| N stage | (N3 vs N2) | 0.741 | 1.078 | 0.691-1.680 | 0.706 | 1.083 | 0.717-1.635 |
| TNM stage | (IV vs III) | 0.004 | 1.750 | 1.194-2.565 | <0.001 | 2.222 | 1.529-3.227 |
Abbreviations: NLR: neutrophil to lymphocyte ratio; PLR: platelet to lymphocyte ratio; LMR: lymphocyte to monocyte ratio; D-D: D-dimer; FIB: fibrinogen; ALB: albumin; HDL: high-density lipoprotein; GGT: gamma-glutamyltransferase; UA: uric acid; CEA: carcino-embryonic antigen; BMI: body mass index.